What a laugh... upgrade profit forecast one month later again by $23-$24m from $63-$70m to $86-$94m and share price does not move.... we must be living on the planet Zork! The upgrade reflects increased testing in VIC. Good testing numbers again today after levelling of in the past week. 89000 in VIC. November and December months still forecast at same NPAT as prospectus. Depending on testing at the same level as October till the end of December NPAT can be well in excess of $100m in first half only. Still the share price has not even moved. Up to 50-70% of NPAT paid as dividend according to dividend policy. Should be decent dividend for H1FY22. But the market does not like the stock. So who can tell where it will go.
ACL Price at posting:
$4.29 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)